HIK

Hikma Pharmaceuticals PLC

Health Care First-pass screen £3.0bn

320/1000 Overall fit

AI beneficiary 35% 25

Operating leverage 25% 40

Valuation 25% 30

Downside protection 15% 35

First-pass take

Generic pharmaceutical manufacturer with stable cash generation but zero AI/ML exposure. Rising leverage (1.6x EBITDA vs 1.4x prior year) and high customer concentration (3 wholesalers = 35% of revenue) limit downside protection. Injectables margin fell 43bp; Branded offsets.

Flags

no-aicustomer-concentrationrising-leverageinjectables-pressureno-valuation-data